None listed
Conditions
Interventions
Dietary Supplement : Experimental group: The main ingredient is Cordyceps militaris Extract, 2 times/day, 2 tablets/time.
Placebo group: The main ingredient is crystaling Cellulose and lactose, 2 tim
Sponsors
Dong-A ST
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Adults aged 20~70 who had suffered more than twice Upper respiratory infection* disorder or common cold causing URI (*(tonsillitis), (pharyngitis), (laryngitis), (sinusitis), (otitis media), (rhinitis)) 2) People who sign the informed consent form before participating in the study
Exclusion criteria
Exclusion criteria: 1) subjects vaccinated against influenza within the last 6 months prior to the study 2) subjects with clinically significant cardiovascular, immune, infectious, or neoplastic disease currently 3) subjects who are under treatment for uncontrolled hypertension, diabetes, thyroid disease etc. (However, subjects can participate in the study based on doctor’s assessment) 4) subjects with Upper respiratory infection at screening visit 5) subjects who have taken medications such as immunosuppressive drugs, corticosteroids within the last 1 months 6) subjects with Allergic or hypersensitive to Cordyceps militaris 7) subjects with mental illness such as depression, schizophrenia, alcoholism, drug addiction 8) subjects whose creatinine level is twice higher than the upper limit 9) subjects whose AST(GOT) or ALT(GPT) level is twice higher than the upper limit 10) subjects with gastrointestinal tract disorder such as heartburn, dyspepsia 11) subjects who have taken functional foods within the last 2 weeks or is taking now for immune health 12) subjects who are pregnant, breast feeding or do not agree to use adequate contraception during this study period (except for surgery for female infertility) 13) subjects who have participated in another study within the last 2 months or scheduled for another study during this study period 14) Inappropriate subject decided by investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The frequency of URI onset | — |
Secondary
| Measure | Time frame |
|---|---|
| severity and duration of URI symptoms;frequency of URI onset at each visit;subjective assessment ;NK cell activity, IFN-?, IL-2, IgA | — |
Countries
Korea, Republic of
Contacts
Public ContactOh mi-ra
Chonbuk National University Hospital
Outcome results
None listed